Clinical Trial

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Protocol Amendment History 3 changes
notable Trial sites expanded: 3 -> 6 locations 2026-08-12
critical Recruitment opened 2026-06-13
notable Trial sites expanded: 0 -> 3 locations 2026-06-13
Trial Details
NCT Number NCT07358377
Lead Sponsor Atridia Pty Ltd.
Conditions Breast Cancer
Enrollment 15 participants
Start Date 2026-05-15
Primary Completion 2027-04-10 (estimated)
Study Completion 2027-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-11